Receptor, erbB-2

"Receptor, erbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Descriptor ID	D018719
MeSH Number(s)	D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
Concept/Terms	Receptor, ErbB-2 Receptor, ErbB-2 ErbB-2 Receptor Antigens, CD340 CD340 Antigens Proto-Oncogene Proteins c-erbB-2 Proto Oncogene Proteins c erbB 2 p185(c-neu) c-erbB-2 Protein c erbB 2 Protein erbB-2 Proto-Oncogene Protein Proto-Oncogene Protein, erbB-2 erbB 2 Proto Oncogene Protein erbB-2 Receptor Protein-Tyrosine Kinase erbB 2 Receptor Protein Tyrosine Kinase neu Proto-Oncogene Protein Proto-Oncogene Protein, neu neu Proto Oncogene Protein HER-2 Proto-Oncogene Protein HER 2 Proto Oncogene Protein Proto-Oncogene Protein, HER-2 Proto-Oncogene Protein HER-2 Proto Oncogene Protein HER 2 Receptors, erbB-2 erbB-2 Receptors Neu Receptor Receptor, Neu Metastatic Lymph Node Gene 19 Protein Proto-oncogene Protein Neu Neu, Proto-oncogene Protein Proto-oncogene c-ErbB-2 c-ErbB-2, Proto-oncogene Tyrosine Kinase-type Cell Surface Receptor HER2 Tyrosine Kinase type Cell Surface Receptor HER2 p185erbB2 Protein CD340 Antigen Oncogene Protein HER-2 Oncogene Protein HER 2 Proto-Oncogene Protein p185(neu)

Below are MeSH descriptors whose meaning is more general than "Receptor, erbB-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptor, ErbB-2 [D12.776.543.750.630.009.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]
Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Receptor, ErbB-2 [D12.776.624.664.700.642]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Receptor, ErbB-2 [D23.050.301.500.600.700]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Receptor, ErbB-2 [D23.050.705.552.600.550]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Receptor, ErbB-2 [D23.101.140.642]

Below are MeSH descriptors whose meaning is related to "Receptor, erbB-2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, erbB-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, erbB-2" by people in this website by year, and whether "Receptor, erbB-2" was a major or minor topic of these publications.

Bar chart showing 100 publications over 22 distinct years, with a maximum of 8 publications in 2017 and 2018 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	1	0	1
2004	4	0	4
2005	2	1	3
2006	1	1	2
2007	3	1	4
2008	3	2	5
2009	1	3	4
2010	4	2	6
2011	2	2	4
2012	2	1	3
2013	2	4	6
2014	3	3	6
2015	3	1	4
2016	2	5	7
2017	4	4	8
2018	7	1	8
2019	3	3	6
2020	2	6	8
2021	0	4	4
2022	0	5	5
2023	0	1	1

Below are the most recent publications written about "Receptor, erbB-2" by people in Profiles.

Bansil S, Silva A, Taniguchi A, Wiedmer C, Fernandez M, Pagano I, Vierkoetter K, Killeen J, Fukui J. Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. Oncologist. 2023 02 08; 28(2):116-122.

View in: PubMed
Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.

View in: PubMed
Liu X, Chipurupalli S, Jiang P, Tavasoli M, Yoo BH, McPhee M, Mazinani S, Francia G, Kerbel RS, Rosen KV. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth. Cell Death Dis. 2022 Aug 06; 13(8):687.

View in: PubMed
Zavala VA, Casavilca-Zambrano S, Navarro-V?squez J, Casta?eda CA, Valencia G, Morante Z, Calder?n M, Abugattas JE, G?mez H, Fuentes HA, Liendo-Picoaga R, Cotrina JM, Monge C, Neciosup SP, Huntsman S, Hu D, S?nchez SE, Williams MA, N??ez-Marrero A, Godoy L, Hechmer A, Olshen AB, Dutil J, Ziv E, Zabaleta J, Gelaye B, V?squez J, G?lvez-Nino M, Enriquez-Vera D, Vidaurre T, Fejerman L. Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1602-1609.

View in: PubMed
Costa-Reis P, Maurer K, Petri MA, Levy Erez D, Zhao X, Faig W, Burnham J, O'Neil K, Klein-Gitelman MS, von Scheven E, Schanberg LE, Sullivan KE. Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis. Lupus Sci Med. 2022 08; 9(1).

View in: PubMed
Moore J, Pal T, Beeghly-Fadiel A, Fadden MK, Munro HM, Dujon SA, Reid S, Tezak A, Blasingame M, Ware J, Blot WJ, Shu XO, Zheng W, Sanderson M, Lipworth L. A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States. Cancer Causes Control. 2022 Apr; 33(4):515-524.

View in: PubMed
Copeland RL, Kanaan Y. New targets in triple-negative breast cancer. Nat Rev Cancer. 2021 12; 21(12):744.

View in: PubMed
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.

View in: PubMed
Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed
Sanderson M, Pal T, Beeghly-Fadiel A, Fadden MK, Dujon SA, Clinton C, Jimenez C, Davis J, Fortune M, Thompson J, Benson K, Conley N, Reid S, Tezak A, Shu XO, Zheng W, Blot WJ, Lipworth L. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States. Cancer Epidemiol Biomarkers Prev. 2021 07; 30(7):1416-1423.

View in: PubMed

People

Explore

Similar Concepts

Top Journals